Viral hepatitis ranks as the fifth cause of morbidity for infectious diseases in Cuba. Epidemics are observed frequently in the population, the hepatitis A virus being the main agent responsible for such epidemics. Previous reports also confirmed the circulation of the hepatitis E virus. From 1998 to 2003, 258 serum samples were collected by the Reference Laboratory on Viral Hepatitis during 33 outbreaks of acute viral hepatitis as well as from 39 sporadic clinical cases. Sera were tested for anti-HAV and anti-HEV IgM by EIA. Overall of the 33 outbreaks studied sera from 12 (36.4%) were positive for anti-HAV IgM only, from 7 (21.2%) were positive for anti-HEV IgM only, and from 14 (42.4%) were positive for antibodies to both viruses. Individually of the 258 sera collected, 137 (53.1%) were positives for anti-HAV IgM, 20 (7.8%) were positives for anti-HEV IgM, 33 (12.8%) were positives for both markers and 68 (26.4%) were negative to both. Of the clinical cases, 4 (10.3%) were positives for anti-HAV IgM, 13 (33.3%) were positives for anti-HEV IgM and 5 (12.8%) were positives for both markers. Seventeen (43.6%) sera were negatives for all viral hepatitis markers available (A-E). A high positivity for HEV was found in outbreaks tested with the kit produced by CIGB. In particular HEV seems to infect individuals of all ages. The results demonstrate the co-circulation of and co-infection with two enterically transmitted viruses; however a higher positivity was observed for anti-HAV than to anti-HEV (53.1% vs. 7.8%) in outbreaks.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.21147DOI Listing

Publication Analysis

Top Keywords

viral hepatitis
16
anti-hev igm
16
clinical cases
12
anti-hav igm
12
sporadic clinical
8
hepatitis virus
8
anti-hav anti-hev
8
positives anti-hav
8
positives anti-hev
8
igm 128%
8

Similar Publications

Article Synopsis
  • The report updates the 1999 CDC Framework for Program Evaluation in Public Health to include new advancements and lessons learned in evaluation and public health.
  • The 2024 framework introduces a nonprescriptive tool with six steps for effective evaluation planning and implementation, while emphasizing engagement, equity, and learning from insights.
  • It serves as a guide for designing evaluations applicable to various programs, enhancing evidence-based decision-making, and improving program outcomes across different areas.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!